The low-density lipoprotein test global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Low-Density Lipoprotein Test Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The low-density lipoprotein test market size has grown steadily in recent years. It will grow from $8.11 billion in 2023 to $8.46 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to research advancements in cardiovascular medicine, increased awareness of heart health, shift in treatment paradigms, clinical guidelines and recommendations, focus on preventive healthcare..
The low-density lipoprotein test market size is expected to see steady growth in the next few years. It will grow to $10.24 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing healthcare expenditure, aging population demographics, rise in cardiovascular disease burden, shift towards personalized medicine, healthcare policy and guidelines.. Major trends in the forecast period include rising cardiovascular disease prevalence, emphasis on preventive healthcare, personalized medicine and treatment, focus on health awareness and education, regulatory guidelines and recommendations..
Order your report now for swift delivery @
Scope Of Low-Density Lipoprotein Test Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Low-Density Lipoprotein Test Market Overview
Market Drivers –
The rise in the prevalence of cardiovascular diseases is expected to propel the growth of the low-density lipoprotein test market going forward. Cardiovascular diseases refer to a type of condition that affects the heart or blood vessels. The LDL test is used to treat cardiovascular diseases by directly measuring low-density lipoprotein levels in the heart. For instance, in October 2022, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, heart disease is the top cause of mortality in the United States for both genders and members of most racial and ethnic groups. Heart disease claimed almost 695,000 people in the United States in 2021, accounting for one in every five deaths. In 2020, the most common type of heart disease, coronary heart disease, killed 375,476 people. Therefore, the rise in the prevalence of cardiovascular diseases is driving the growth of the low-density lipoprotein test market.
Market Trends –
Product innovations are a key trend gaining popularity in the low-density lipoprotein test markets. Major companies operating in the low-density lipoprotein test market are introducing innovative products to sustain their position in the market. For instance, in December 2021, Novartis AG, a Switzerland-based multinational pharmaceutical corporation, launched Leqvio (Inclisiran), a first-in-class siRNA (small interfering RNA therapy) to lower low-density lipoprotein cholesterol. This medication provides effective and sustained reductions in low-density lipoprotein cholesterol. Leqvio is the first and only small interfering RNA (siRNA) medication for lowering LDL-C (bad cholesterol) that has received FDA approval, requiring just two maintenance doses per year. For some patients with atherosclerotic cardiovascular disease (ASCVD) receiving maximally tolerated statin therapy, Leqvio offers an effective and long-lasting LDL-C decrease of up to 52% in comparison to placebo. Leqvio is a ground-breaking method to reduce LDL-C that also opens new opportunities for how healthcare systems can affect cardiovascular disease.
The low-density lipoprotein test market covered in this report is segmented –
1) By Product Type: LDL-C, LDL-P, LDL-B, Other Products
2) By Component: Kits, Reagents, Devices, Other Components
3) By Disease Type: Diabetes, Stroke, Atherosclerosis, Obesity, Dyslipidaemia, Carotid Artery Disease, Peripheral Arterial Disease, Angina, Other Disease Types
4) By Distribution Channel: Direct Tenders, Retail
5) By End User: Hospitals, Clinics, Ambulatory Care, Research Laboratory, Other End Users
Get an inside scoop of the low-density lipoprotein test market, Request now for Sample Report @
Regional Insights –
North America was the largest region in the Low-Density Lipoprotein Test market in 2023. The regions covered in the low-density lipoprotein test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the low-density lipoprotein test market report are Abbott Laboratories, Qiagen N.V., Randox Laboratories Ltd., Eurofins Scientific SE, Danaher Corporation, Bio-Rad Laboratories Inc., OPKO Health Inc., Lincoln Diagnostics LLC, DiaSorin S.p.A., Boster Biological Technology Ltd., Rockland Immunochemicals Inc., Sekisui Diagnostics LLC, DiaSys Diagnostic Systems GmbH, Eurolyser Diagnostica GmbH, Diazyme Laboratories Inc., Cell Biolabs Inc, Home Access Health Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Quest Diagnostics Incorporated, SpectraCell Laboratories Inc., Siemens AG, Alfa Wassermann Inc., Laboratory Corporation of America Holdings, Merck KGaA, F Hoffmann-La Roche Ltd., Agilent Technologies Inc., BioVision Incorporated, Abcam plc, BioAssay Systems, BioChain Institute Inc., BioLegend Inc., Bioo Scientific LLC, Enzo Life Sciences Inc., GenScript Biotech Corporation .
Table of Contents
1. Executive Summary
2. Low-Density Lipoprotein Test Market Report Structure
3. Low-Density Lipoprotein Test Market Trends And Strategies
4. Low-Density Lipoprotein Test Market – Macro Economic Scenario
5. Low-Density Lipoprotein Test Market Size And Growth
…..
27. Low-Density Lipoprotein Test Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
Twitter: https://twitter.com/tbrc_info
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
